Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie最新文献_第9页

Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy. 优化带有 CD8α spacer 和基于 TNFR 的成本刺激的抗 TIM3 嵌合抗原受体，提高急性髓细胞白血病治疗的疗效。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1016/j.biopha.2024.117388

Kristine Cate S Pe, Sirirut Jewmoung, Sm Ali Hosseini Rad, Natthida Chantarat, Chantiya Chanswangphuwana, Haruko Tashiro, Koramit Suppipat, Supannikar Tawinwung

{"title":"Optimization of anti-TIM3 chimeric antigen receptor with CD8α spacer and TNFR-based costimulation for enhanced efficacy in AML therapy.","authors":"Kristine Cate S Pe, Sirirut Jewmoung, Sm Ali Hosseini Rad, Natthida Chantarat, Chantiya Chanswangphuwana, Haruko Tashiro, Koramit Suppipat, Supannikar Tawinwung","doi":"10.1016/j.biopha.2024.117388","DOIUrl":"10.1016/j.biopha.2024.117388","url":null,"abstract":"CAR T cell therapy for AML remains limited due to the lack of a proper target without on-target off-tumor toxicity. TIM3 is a promising target due to its high expression on AML cells and absence in most normal hematopoietic cells. Previous reports have shown that each CAR component impacts CAR functionality. Here, we optimized TIM-3 targeting CAR T cells for AML therapy. We generated CARs targeting TIM3 with two different non-signaling domains: an IgG2-CH3 spacer with CD28 transmembrane domain (CH3/CD28) and a CD8α spacer with CD8α transmembrane domain (CD8/CD8), and evaluated their characteristics and function. Incorporating the non-signaling CH3/CD28 domain resulted in unstable CAR expression in anti-TIM3 CAR T cells, leading to lower surface CAR expression over time and reduced cytotoxic function compared to anti-TIM3 CARs with the CD8/CD8 domain. Both types of anti-TIM3 CAR T cells transiently exhibited fratricide, which subsided overtime, and both CAR T cells achieved substantial T cell expansion. To further optimize the design, we explored the effects of different costimulatory domains. Compared with CD28 costimulation, 4-1BB and CD27 combined with a CD8/CD8 non-signaling domain showed higher cytokine secretion, superior antitumor activity, and enhanced T-cell persistence after repeated antigen exposure. These findings emphasize the impact of the optimal design of CAR constructs that provide efficient function. In the context of anti-TIM3 CAR T cells, using a CD8α spacer and transmembrane domain with TNFR-based costimulation is a promising CAR design to improve anti-TIM3 CAR T cell function for AML therapy.","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"179 ","pages":"117388"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to "Lactobacillus rhamnosus GG coating with nanocomposite ameliorates intestinal inflammation" [Biomed. Pharmacother. 178 (2024) 117-197]. 鼠李糖乳杆菌 GG 涂覆纳米复合材料可改善肠道炎症》[Biomed. Pharmacother. 178 (2024) 117-197] 更正。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-10-01 Epub Date: 2024-09-10 DOI: 10.1016/j.biopha.2024.117434

Zihan Zhai, Xin Wang, Zhanyin Qian, Aili Wang, Wenjing Zhao, Jie Xiong, Jingyi Wang, Yinsong Wang, Hailong Cao

引用次数: 0

Retraction notice to "Overexpression of macrophage stimulating 1 enhances the anti-tumor effects of IL-24 in esophageal cancer via inhibiting ERK-Mfn2 signaling-dependent mitophagy" [Biomed. Pharmacother. 114 (2019) 108844]. 关于 "Overexpression of macrophage stimulating 1 enhances the anti-tumor effects of IL-24 in esophageal cancer via inhibiting ERK-Mfn2 signaling-dependent mitophagy "的撤稿通知 [Biomed. Pharmacother. 114 (2019) 108844]。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-10-01 Epub Date: 2024-09-14 DOI: 10.1016/j.biopha.2024.117355

Jianpeng Zhang, Lin Sun, Weiqiang Li, Yanyu Wang, Xinzhen Li, Yang Liu

引用次数: 0

Corrigendum to "3D printed PLGA scaffold with nano-hydroxyapatite carrying linezolid for treatment of infected bone defects" [Biomed. Pharmacother. 172 (2024) 116228]. 对 "含有纳米羟基磷灰石的三维打印 PLGA 支架用于治疗感染性骨缺损"[Biomed. Pharmacother.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-10-01 Epub Date: 2024-09-04 DOI: 10.1016/j.biopha.2024.117212

A Li Mu Ke Re Mu, Zhi Lin Liang, Linlin Chen, Ai Ke Bai Er Tu Xun, Mai Mai Ti Ai Li A Bu Li Ke Mu, Yuan Quan Wu

引用次数: 0

Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122⁺CXCR3⁺PD-1^- memory T cells. 黄芪多糖通过增加 CD122+CXCR3+PD-1- 记忆 T 细胞，增强嵌合抗原受体工程（CAR）T 细胞的抗肿瘤效果。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1016/j.biopha.2024.117401

Qunfang Zhang, Chunzhao Su, Yini Luo, Fang Zheng, Chun-Ling Liang, Yuchao Chen, Huazhen Liu, Feifei Qiu, Yunshan Liu, Wenxuan Feng, Zhenhua Dai

{"title":"Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122+CXCR3+PD-1- memory T cells.","authors":"Qunfang Zhang, Chunzhao Su, Yini Luo, Fang Zheng, Chun-Ling Liang, Yuchao Chen, Huazhen Liu, Feifei Qiu, Yunshan Liu, Wenxuan Feng, Zhenhua Dai","doi":"10.1016/j.biopha.2024.117401","DOIUrl":"10.1016/j.biopha.2024.117401","url":null,"abstract":"Chimeric antigen receptor-engineered T (CAR-T) cell therapy of cancer has been a hotspot and promising. However, due to rapid exhaustion, CAR-T cells are less effective in solid tumors than in hematological ones. CD122+CXCR3+ memory T cells are characterized with longevity, self-renewal and great antitumoral capacity. Thus, it's compelling to induce memory CAR-T cells to enhance their efficacy on solid tumors. Astragalus polysaccharide (APS) has reportedly exhibited antitumoral effects. However, it's unclear if APS has an impact on CD8+ memory T cell generation or persistence. Using two human cancer cell lines, here we found that APS significantly improved the persistence of GPC3-targeted CAR-T cells and enhanced their suppression of tumor growth in both Huh7 and HepG2 xenograft models of hepatocellular carcinoma. APS increased CD122+/CXCR3+ memory T cells, but decreased their PD-1+ subset within CD8+ CAR-T cells in tumor-bearing mice, while these effects of APS were also confirmed with in vitro experiments. Moreover, APS augmented the expression of chemokines CXCL9/CXCL10 by the tumor in vivo and in vitro. It also enhanced the proliferation and chemotaxis/migration of CAR-T cells in vitro. Finally, APS promoted the phosphorylation of STAT5 in CD8+ CAR-T cells, whereas inhibition of STAT5 activation reversed these in vitro effects of APS. Therefore, APS enhanced the antitumoral effects of CD8+ CAR-T cells by promoting formation/persistence of CD122+/CXCR3+/PD-1- memory T cells and their migration to the tumor.","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"179 ","pages":"117401"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction notice to "Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ" [Biomed. Pharmacother. 103 (2018) 272-283]. Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPARγ" [Biomed. Pharmacother. 103 (2018) 272-283] 的撤稿通知。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-10-01 Epub Date: 2024-09-14 DOI: 10.1016/j.biopha.2024.117354

Mei Han, Hui Gao, Ping Ju, Ming-Quan Gao, Yin-Ping Yuan, Xue-Hong Chen, Kai-Li Liu, Yan-Tao Han, Zhi-Wu Han

引用次数: 0

Scent of relief: Mastic resin scent recovers salivation in chronic dry mouth patients. 缓解的香味松香树脂的香味能恢复慢性口干症患者的唾液分泌。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1016/j.biopha.2024.117245

Mouri R J Faruque, Wiktoria Potocka, Kamran Nazmi, Antoon J Ligtenberg, Floris J Bikker, Marja L Laine

{"title":"Scent of relief: Mastic resin scent recovers salivation in chronic dry mouth patients.","authors":"Mouri R J Faruque, Wiktoria Potocka, Kamran Nazmi, Antoon J Ligtenberg, Floris J Bikker, Marja L Laine","doi":"10.1016/j.biopha.2024.117245","DOIUrl":"10.1016/j.biopha.2024.117245","url":null,"abstract":"Background: Olfactory stimulation with mastic resin, derived from the Pistacia lentiscus tree, demonstrated a bona fide sialagogic effect in healthy volunteers [1]. Its main volatile compound, α-pinene, also showed this effect. The current study aimed to validate the effect of mastic resin volatiles in chronic dry mouth patients with confirmed decreased saliva secretion.Methods: 41 chronic dry mouth patients with decreased unstimulated saliva secretion (<0.25 mL/min) were exposed to mastic resin volatiles as part of the diagnostic routine at the Saliva Clinic of Academic Centre for Dentistry Amsterdam. During their visit, dry-mouth questionnaires were conducted and samples of unstimulated whole saliva, chew-stimulated saliva, acid-stimulated saliva and mastic resin stimulated saliva were collected. Saliva flow rate, spinnbarkeit, pH, ion composition, MUC5B and MUC7 levels in all samples were analyzed.Results: Salivary flow rates increased by all stimuli when compared to the baseline unstimulated saliva (P<0.001). During olfactory mastic resin stimulation, the salivary spinnbarkeit (P<0.001) and sodium concentration (P<0.01) were increased compared to unstimulated saliva. MUC5B and MUC7 levels were increased during olfactory mastic resin stimulation compared to chew-stimulated saliva (P=0.016 and P<0.001, respectively). Spinnbarkeit correlated positively with MUC5B (R=0.399, P=0.002) and MUC7 levels (R=0.375, P=0.004). Results of dry-mouth questionnaires indicated reduced posterior palate dryness shortly after olfactory mastic resin stimulation (P=0.04).Conclusions: Olfactory mastic resin stimulation increased mucous saliva secretion and reduced posterior palate dryness in a group of chronic dry mouth patients. These findings, validated in patients, underscore mastic resin scent as a beneficial and non-invasive sialagogic treatment for clinical applications.","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117245"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis. PTX-RPPR，一种紫杉醇和 NRP-1 肽抑制剂的共轭物，用于防止肿瘤生长和转移。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-14 DOI: 10.1016/j.biopha.2024.117264

Yuanyuan Li, Qiqi Feng, Qi Gao, Yaonan Wang, Shurui Zhao, Xiaoyi Zhang, Ming Zhao

{"title":"PTX-RPPR, a conjugate of paclitaxel and NRP-1 peptide inhibitor to prevent tumor growth and metastasis.","authors":"Yuanyuan Li, Qiqi Feng, Qi Gao, Yaonan Wang, Shurui Zhao, Xiaoyi Zhang, Ming Zhao","doi":"10.1016/j.biopha.2024.117264","DOIUrl":"10.1016/j.biopha.2024.117264","url":null,"abstract":"Paclitaxel, a potent anti-tumor drug widely recognized for its therapeutic efficacy, has faced limitations in clinical application due to its poor solubility. The use of Cremophor EL (CrEL) as a cosolvent in paclitaxel injections has been associated with hypersensitivity reactions in some patients. To overcome these challenges, we have developed a novel conjugate by linking a neuropilin-1 targeting peptide, RPPR, to paclitaxel, resulting in PTX-RPPR. This innovative approach has significantly enhanced the solubility of paclitaxel, achieving a 3.8 mg/mL concentration, a remarkable 90-fold increase over the native drug. PTX-RPPR has shown potent anti-tumor activity, inhibiting tumor cell proliferation with an IC50 ranging from 0.26 to 1.64 μM and effectively suppressing migration, invasion, and angiogenesis at a concentration of 75 nM. Notably, in a 4T1 mammary carcinoma model, PTX-RPPR administered at a dose of 0.7 μmol/kg exhibited tumor growth inhibition comparable to that of paclitaxel at a higher dose of 3.5 μmol/kg, with superior efficacy in preventing lung metastasis. Furthermore, PTX-RPPR effectively reduced NRP-1 expression in both tumors and lungs post-treatment. In contrast to paclitaxel formulated with CrEL, PTX-RPPR did not induce IL-6 expression, suggesting a safer profile in terms of immunological response. Characterized by a particle size of 200 nm and a zeta potential of +30 mV, the nano-formulation of PTX-RPPR demonstrated remarkable stability over seven days. This study introduced PTX-RPPR as a promising peptide-drug conjugate that addresses the solubility and hypersensitivity issues associated with paclitaxel, offering a safer therapeutic strategy for cancer treatment.","PeriodicalId":93904,"journal":{"name":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","volume":"178 ","pages":"117264"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction notice to 'MiR-370 functions as oncogene in melanoma by direct targeting pyruvate dehydrogenase B' [Biomedicine & Pharmacotherapy, Volume 90 (2017) Pages 278-286]. MiR-370通过直接靶向丙酮酸脱氢酶B在黑色素瘤中发挥癌基因功能》的撤稿通知[《生物医学与药物治疗》，第90卷（2017），第278-286页]。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-07-21 DOI: 10.1016/j.biopha.2024.117168

Shufang Wei, Weiyuan Ma

引用次数: 0

Corrigendum to "Berberine mitigates cognitive decline in an Alzheimer's Disease Mouse Model by targeting both tau hyperphosphorylation and autophagic clearance" [Biomed. Pharmacother. 121 (2020) 109670]. 小檗碱通过靶向 tau 过度磷酸化和自噬清除减轻阿尔茨海默病小鼠模型的认知能力下降》[Biomed. Pharmacother. 121 (2020) 109670]的更正。

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Pub Date : 2024-09-01 Epub Date: 2024-08-03 DOI: 10.1016/j.biopha.2024.117250

Ying Chen, Yuling Chen, Yubin Liang, Hongda Chen, Xiaoying Ji, Min Huang

引用次数: 0